<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">Am J Gastroenterol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>The American journal of gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">0002-9270</issn><issn pub-type="epub">1572-0241</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11534529</article-id><article-id pub-id-type="pmcid-ver">PMC11534529.1</article-id><article-id pub-id-type="pmcaid">11534529</article-id><article-id pub-id-type="pmcaiid">11534529</article-id><article-id pub-id-type="manuscript-id">NIHMS2002156</article-id><article-id pub-id-type="pmid">38888231</article-id><article-id pub-id-type="doi">10.14309/ajg.0000000000002891</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2002156</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2002156</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Natural History after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Population-Based Cohort Study from the United States</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Barnes</surname><given-names initials="EL">Edward L.</given-names></name><degrees>MD, MPH</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Desai</surname><given-names initials="A">Aakash</given-names></name><degrees>MD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hashash</surname><given-names initials="JG">Jana G.</given-names></name><degrees>MD, MSc</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Farraye</surname><given-names initials="FA">Francis A.</given-names></name><degrees>MD, MSc</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kochhar</surname><given-names initials="GS">Gursimran S.</given-names></name><degrees>MD</degrees><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC</aff><aff id="A2"><label>2</label>Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC</aff><aff id="A3"><label>3</label>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC</aff><aff id="A4"><label>4</label>Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL</aff><aff id="A5"><label>5</label>Division of Gastroenterology, Hepatology &amp; Nutrition, Allegheny Health Network,Pittsburgh, Pennsylvania, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Specific author contributions:</p><p id="P2">ELB: study planning, oversight of the study, interpretation of the data, writing of the initial draft of the manuscript, critical revision of the manuscript.</p><p id="P3">AD: study planning, oversight of the study, data acquisition, conduction of the study and statistical analysis, interpretation of the data, critical revision of the manuscript.</p><p id="P4">JGH: study planning, oversight of the study, interpretation of the data, critical revision of the manuscript.</p><p id="P5">FAF: study planning, oversight of the study, interpretation of the data, critical revision of the manuscript.</p><p id="P6">GSK: study planning, oversight of the study, data acquisition, interpretation of the data, critical revision of the manuscript.</p></fn><corresp id="CR1"><underline>Corresponding Author:</underline> Edward L. Barnes, MD, MPH, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Campus Box #7080, 130 Mason Farm Road, Chapel Hill, NC 27599-7080, Fax: 919-966-6842, <email>edward_barnes@med.unc.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P34">Potential Competing Interests:</p><p id="P35">Edward L. Barnes has served as a consultant for AbbVie.</p><p id="P36">Aakash Desai: None</p><p id="P37">Jana G. Hashash: Advisory Board for BMS.</p><p id="P38">Francis A. Farraye: Consultant for AbbVie, Avalo Therapeutics, BMS, Braintree Labs, Fresenius Kabi, GI Reviewers, GSK, IBD Educational Group, Iterative Health, Janssen, Pharmacosmos, Pfizer, Sandoz Immunology, Sebela, Viatris. DSMB for Eli Lilly</p><p id="P39">Gursimran Kochhar: Advisor Board: Lilly USA, CorVetas research foundation, GIE medical; Speaker: Lilly Pharma; Consultant: Pentax Endoscopy, Boston Scientific; Stock Options: DigbiHealth</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2024</year></pub-date><volume>119</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">474324</issue-id><fpage>2267</fpage><lpage>2274</lpage><pub-history><event event-type="nihms-submitted"><date><day>25</day><month>06</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-05 17:25:33.103"><day>05</day><month>11</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2002156.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P7">There are limited data regarding the natural history after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The principal objectives of this study were to identify 4 key outcomes in the natural history after IPAA within 1-, 3-, 5- and 10-years: the incidence of pouchitis, Crohn&#8217;s-like disease of the pouch (CLDP), use of advanced therapies after IPAA, and pouch failure requiring excision in a network of electronic health records (EHRs).</p></sec><sec id="S2"><title>Methods:</title><p id="P8">We performed a retrospective cohort study in TriNetX, a research network of EHRs. In addition to evaluating incidence rates, we also sought to identify factors associated with pouchitis and advanced therapy use within 5 years of IPAA after 1:1 propensity score matching (PSM), expressed as adjusted Hazard Ratios (aHRs).</p></sec><sec id="S3"><title>Results:</title><p id="P9">Among 1,331 patients who underwent colectomy with IPAA for UC, the incidence of pouchitis increased from 58% in the first year after IPAA to 72% at 10 years after IPAA. After PSM, nicotine dependence (aHR 1.61, 95% CI 1.19&#8211;2.18) and anti-TNF therapy (aHR 1.33, 95% CI 1.13&#8211;1.56) and vedolizumab prior to colectomy (aHR 1.44, 95% CI 1.06&#8211;1.96) were associated with an increased risk of pouchitis in the first 5 years after IPAA. The incidence of CLDP increased to 10.3% within 10 years of IPAA while pouch failure increased to 4.1%. The incidence of advanced therapy use peaked at 14.4% at 10 years after IPAA.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P10">The incidence of inflammatory conditions of the pouch remains high in the current era, with 14% of patients requiring advanced therapies after IPAA.</p></sec></abstract><kwd-group><kwd>pouchitis</kwd><kwd>advanced therapy</kwd><kwd>J-pouch</kwd><kwd>epidemiology</kwd><kwd>biologic</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>